EANS-EANO Guidelines on the extent of resection in gliomas.

IF 13.4 1区 医学 Q1 CLINICAL NEUROLOGY
Roland Goldbrunner, Nicolas Foroglou, Francesco Signorelli, Philippe Schucht, Asgeir S Jakola, Giuseppe Minniti, Radoslaw Rola, Mirjam Renovanz, Matthias Preusser, Julia Furtner, Rachel Grossman, Christian Mawrin, Andreas Demetriades, Michael Weller, Matthias Simon
{"title":"EANS-EANO Guidelines on the extent of resection in gliomas.","authors":"Roland Goldbrunner, Nicolas Foroglou, Francesco Signorelli, Philippe Schucht, Asgeir S Jakola, Giuseppe Minniti, Radoslaw Rola, Mirjam Renovanz, Matthias Preusser, Julia Furtner, Rachel Grossman, Christian Mawrin, Andreas Demetriades, Michael Weller, Matthias Simon","doi":"10.1093/neuonc/noaf217","DOIUrl":null,"url":null,"abstract":"<p><p>Intense efforts are employed to optimize neurosurgical resection of gliomas in different clinical scenarios. However, the level of evidence employed towards personalised treatment decisions is still moderate. Therefore, a joint task force was created by the European Association for Neurosurgical Societies (EANS) and the European Association of Neuro-Oncology (EANO) in order to provide interdisciplinary guidance on the extent of resection (EOR) in glioma surgery. This task force assessed the data on the EOR in gliomas, evaluated the level of evidence and composed recommendations. The EOR is determined routinely by postoperative magnetic resonance imaging (MRI). Since EOR may be associated with survival and may have an impact on epilepsy, neurocognition, quality of life, neurological status and also on planning of radiation and pharmacotherapy (evidence classes I-IV), recommendations of different levels can be made for the resection of newly diagnosed glioblastomas (level A), recurrent glioblastomas (level C), newly diagnosed (level B) and recurrent (good practice point) IDH mutant gliomas, ependymomas in children (level B) and adults (good practice point) as well as World Health Organization (WHO) CNS grade 1 tumors (good practice point). We hereby report the outcome of this collaborative effort by the joint task force between EANS and EANO.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":""},"PeriodicalIF":13.4000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/neuonc/noaf217","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Intense efforts are employed to optimize neurosurgical resection of gliomas in different clinical scenarios. However, the level of evidence employed towards personalised treatment decisions is still moderate. Therefore, a joint task force was created by the European Association for Neurosurgical Societies (EANS) and the European Association of Neuro-Oncology (EANO) in order to provide interdisciplinary guidance on the extent of resection (EOR) in glioma surgery. This task force assessed the data on the EOR in gliomas, evaluated the level of evidence and composed recommendations. The EOR is determined routinely by postoperative magnetic resonance imaging (MRI). Since EOR may be associated with survival and may have an impact on epilepsy, neurocognition, quality of life, neurological status and also on planning of radiation and pharmacotherapy (evidence classes I-IV), recommendations of different levels can be made for the resection of newly diagnosed glioblastomas (level A), recurrent glioblastomas (level C), newly diagnosed (level B) and recurrent (good practice point) IDH mutant gliomas, ependymomas in children (level B) and adults (good practice point) as well as World Health Organization (WHO) CNS grade 1 tumors (good practice point). We hereby report the outcome of this collaborative effort by the joint task force between EANS and EANO.

胶质瘤切除范围的EANS-EANO指南。
在不同的临床情况下,神经外科手术切除胶质瘤是一项非常重要的研究。然而,用于个性化治疗决策的证据水平仍然是温和的。因此,欧洲神经外科学会协会(EANS)和欧洲神经肿瘤协会(EANO)成立了一个联合工作组,以提供胶质瘤手术中切除程度(EOR)的跨学科指导。该工作组评估了胶质瘤EOR的数据,评估了证据水平并提出了建议。EOR通过术后磁共振成像(MRI)常规测定。由于EOR可能与生存有关,并可能对癫痫、神经认知、生活质量、神经状态以及放射和药物治疗的规划产生影响(证据等级I-IV),因此对于新诊断的胶质母细胞瘤(A级)、复发性胶质母细胞瘤(C级)、新诊断的(B级)和复发性IDH突变胶质瘤(良好实践点)的切除,可以提出不同级别的建议。儿童室管膜瘤(B级)和成人(良好实践点)以及世界卫生组织(WHO)中枢神经系统1级肿瘤(良好实践点)。兹报告东亚经委会和东亚经委会联合工作组的合作成果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Neuro-oncology
Neuro-oncology 医学-临床神经学
CiteScore
27.20
自引率
6.30%
发文量
1434
审稿时长
3-8 weeks
期刊介绍: Neuro-Oncology, the official journal of the Society for Neuro-Oncology, has been published monthly since January 2010. Affiliated with the Japan Society for Neuro-Oncology and the European Association of Neuro-Oncology, it is a global leader in the field. The journal is committed to swiftly disseminating high-quality information across all areas of neuro-oncology. It features peer-reviewed articles, reviews, symposia on various topics, abstracts from annual meetings, and updates from neuro-oncology societies worldwide.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信